3zpq › Citations

Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design.

Chart 1
Figure 1
Chart 2
Christopher JA, Brown J, Doré AS, Errey JC, Koglin M, Marshall FH, Myszka DG, Rich RL, Tate CG, Tehan B, Warne T, Congreve M
OpenAccess logo J Med Chem 56 3446-55 (2013)
Cited: 79 times
EuropePMC logo PMID: 23517028

Abstract

Biophysical fragment screening of a thermostabilized β1-adrenergic receptor (β1AR) using surface plasmon resonance (SPR) enabled the identification of moderate affinity, high ligand efficiency (LE) arylpiperazine hits 7 and 8. Subsequent hit to lead follow-up confirmed the activity of the chemotype, and a structure-based design approach using protein-ligand crystal structures of the β1AR resulted in the identification of several fragments that bound with higher affinity, including indole 19 and quinoline 20. In the first example of GPCR crystallography with ligands derived from fragment screening, structures of the stabilized β1AR complexed with 19 and 20 were determined at resolutions of 2.8 and 2.7 Å, respectively.

Reviews - 3zpq mentioned but not cited (4)

  1. G protein-coupled receptors: structure- and function-based drug discovery. Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, Wu Y, Yuliantie E, Xie L, Tao H, Cheng J, Liu Q, Zhao S, Shui W, Jiang Y, Wang MW. Signal Transduct Target Ther 6 7 (2021)
  2. Harnessing Ion-Binding Sites for GPCR Pharmacology. Zarzycka B, Zaidi SA, Roth BL, Katritch V. Pharmacol Rev 71 571-595 (2019)
  3. Structural Studies of G Protein-Coupled Receptors. Zhang D, Zhao Q, Wu B. Mol Cells 38 836-842 (2015)
  4. Recent Insights from Molecular Dynamics Simulations for G Protein-Coupled Receptor Drug Discovery. Zou Y, Ewalt J, Ng HL. Int J Mol Sci 20 E4237 (2019)

Articles - 3zpq mentioned but not cited (12)



Reviews citing this publication (26)

  1. Twenty years on: the impact of fragments on drug discovery. Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H. Nat Rev Drug Discov 15 605-619 (2016)
  2. Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. Patching SG. Biochim Biophys Acta 1838 43-55 (2014)
  3. Biophysics in drug discovery: impact, challenges and opportunities. Renaud JP, Chung CW, Danielson UH, Egner U, Hennig M, Hubbard RE, Nar H. Nat Rev Drug Discov 15 679-698 (2016)
  4. Cholesterol, sphingolipids, and glycolipids: what do we know about their role in raft-like membranes? Róg T, Vattulainen I. Chem Phys Lipids 184 82-104 (2014)
  5. Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis. Olaru A, Bala C, Jaffrezic-Renault N, Aboul-Enein HY. Crit Rev Anal Chem 45 97-105 (2015)
  6. Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. Schuetz DA, de Witte WEA, Wong YC, Knasmueller B, Richter L, Kokh DB, Sadiq SK, Bosma R, Nederpelt I, Heitman LH, Segala E, Amaral M, Guo D, Andres D, Georgi V, Stoddart LA, Hill S, Cooke RM, De Graaf C, Leurs R, Frech M, Wade RC, de Lange ECM, IJzerman AP, Müller-Fahrnow A, Ecker GF. Drug Discov Today 22 896-911 (2017)
  7. What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands? Michino M, Beuming T, Donthamsetti P, Newman AH, Javitch JA, Shi L. Pharmacol Rev 67 198-213 (2015)
  8. New paradigms in GPCR drug discovery. Jacobson KA. Biochem Pharmacol 98 541-555 (2015)
  9. Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design. Basith S, Cui M, Macalino SJY, Park J, Clavio NAB, Kang S, Choi S. Front Pharmacol 9 128 (2018)
  10. Structural features of the G-protein/GPCR interactions. Moreira IS. Biochim Biophys Acta 1840 16-33 (2014)
  11. How Can Mutations Thermostabilize G-Protein-Coupled Receptors? Vaidehi N, Grisshammer R, Tate CG. Trends Pharmacol Sci 37 37-46 (2016)
  12. GPCR crystal structures: Medicinal chemistry in the pocket. Shonberg J, Kling RC, Gmeiner P, Löber S. Bioorg Med Chem 23 3880-3906 (2015)
  13. Large-scale production and protein engineering of G protein-coupled receptors for structural studies. Milić D, Veprintsev DB. Front Pharmacol 6 66 (2015)
  14. Ligands of Adrenergic Receptors: A Structural Point of View. Wu Y, Zeng L, Zhao S. Biomolecules 11 936 (2021)
  15. Successful generation of structural information for fragment-based drug discovery. Öster L, Tapani S, Xue Y, Käck H. Drug Discov Today 20 1104-1111 (2015)
  16. Structure-based and fragment-based GPCR drug discovery. Andrews SP, Brown GA, Christopher JA. ChemMedChem 9 256-275 (2014)
  17. Accurate determination of protein:ligand standard binding free energies from molecular dynamics simulations. Fu H, Chen H, Blazhynska M, Goulard Coderc de Lacam E, Szczepaniak F, Pavlova A, Shao X, Gumbart JC, Dehez F, Roux B, Cai W, Chipot C. Nat Protoc 17 1114-1141 (2022)
  18. Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors. Chaturvedi M, Schilling J, Beautrait A, Bouvier M, Benovic JL, Shukla AK. Trends Biochem Sci 43 533-546 (2018)
  19. Developments in SPR Fragment Screening. Chavanieu A, Pugnière M. Expert Opin Drug Discov 11 489-499 (2016)
  20. Discovery of GPCR ligands for probing signal transduction pathways. Brogi S, Tafi A, Désaubry L, Nebigil CG. Front Pharmacol 5 255 (2014)
  21. Structures of mGluRs shed light on the challenges of drug development of allosteric modulators. Bennett KA, Doré AS, Christopher JA, Weiss DR, Marshall FH. Curr Opin Pharmacol 20 1-7 (2015)
  22. Allosteric modulation of G protein-coupled receptors by amiloride and its derivatives. Perspectives for drug discovery? Massink A, Amelia T, Karamychev A, IJzerman AP. Med Res Rev 40 683-708 (2020)
  23. Allosteric Modulation of Adenosine A2A Receptors as a New Therapeutic Avenue. Korkutata M, Agrawal L, Lazarus M. Int J Mol Sci 23 2101 (2022)
  24. The use of conformationally thermostabilised GPCRs in drug discovery: application to fragment, structure and biophysical techniques. Tehan BG, Christopher JA. Curr Opin Pharmacol 30 8-13 (2016)
  25. Engineering of Challenging G Protein-Coupled Receptors for Structure Determination and Biophysical Studies. Waltenspühl Y, Ehrenmann J, Klenk C, Plückthun A. Molecules 26 1465 (2021)
  26. IUPHAR themed review: Opioid efficacy, bias, and selectivity. Ramos-Gonzalez N, Paul B, Majumdar S. Pharmacol Res 197 106961 (2023)

Articles citing this publication (37)



Quick links